Fractyl Health (NASDAQ:GUTS) Receives “Buy” Rating from HC Wainwright

Fractyl Health (NASDAQ:GUTS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $8.00 price target on the stock.

A number of other brokerages also recently commented on GUTS. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS traded up $0.02 during midday trading on Thursday, hitting $0.78. The company’s stock had a trading volume of 774,106 shares, compared to its average volume of 4,084,680. The business’s 50 day simple moving average is $0.66 and its 200 day simple moving average is $1.10. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The company has a market cap of $124.22 million, a P/E ratio of -0.61 and a beta of 2.34. Fractyl Health has a 12-month low of $0.38 and a 12-month high of $3.03.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. On average, analysts forecast that Fractyl Health will post -0.6 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently made changes to their positions in the stock. Pale Fire Capital SE increased its position in shares of Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after acquiring an additional 2,711,103 shares during the last quarter. Accredited Investors Inc. acquired a new stake in shares of Fractyl Health during the first quarter valued at about $46,000. Virtu Financial LLC acquired a new position in shares of Fractyl Health in the fourth quarter valued at approximately $153,000. Susquehanna Portfolio Strategies LLC acquired a new position in shares of Fractyl Health in the fourth quarter valued at approximately $108,000. Finally, Quadrature Capital Ltd grew its holdings in shares of Fractyl Health by 2,047.1% in the fourth quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock valued at $640,000 after purchasing an additional 277,174 shares in the last quarter.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.